Item no. |
HY-15420-500mg |
Manufacturer |
MedChem Express
|
CASRN |
2854-32-2 |
Amount |
500 mg |
Quantity options |
100 mg
10mM/1mL
10 mg
500 mg
50 mg
5 mg
|
Category |
|
Type |
Inhibitors |
Specific against |
other |
Purity |
99.54 |
Formula |
C23H23ClN2O4 |
Citations |
[1]Zhang, Qiang; Ma, Peng; Cole, Richard B.; Wang, Guangdi In vitro metabolism of indomethacin morpholinylamide (BML-190), an inverse agonist for the peripheral cannabinoid receptor (CB2) in rat liver microsomes. European Journal of Pharmaceutical Sciences (2010), 41(1), 163-172.<br/>[2]Klegeris, Andis; Bissonnette, Christopher J.; McGeer, Patrick L. Reduction of human monocytic cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2 receptor. British Journal of Pharmacology (2003), 139(4), 775-786.<br/>[3]New DC, Wong YH. BML-190 and AM251 act as inverse agonists at the human cannabinoid CB2 receptor: signalling via cAMP and inositol phosphates. FEBS Lett. 2003 Feb 11;536(1-3):157-60. |
Smiles |
CC(N1C(C2=CC=C(Cl)C=C2)=O)=C(CC(N3CCOCC3)=O)C4=C1C=CC(OC)=C4 |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
Indomethacin morpholinylamide; IMMA |
Available |
|
Product Description |
BML-190(IMMA) is a potent and selective CB2 receptor ligand (Ki values are 435 nM and > 2 μM for CB2 and CB1 respectively). IC50 Value: 435 nM(Ki CB2) Target:CB2 receptor in vitro: BML-190 increases the accumulation of cAMP, via forskolin-stimulated mechanism in HEK-293 cells. Alternate studies suggest that BML-190 reduces the toxicity of culture supernatants to SH-SY5Y human neutroblastoma cells. Various research suggests that BML-190 is an essential tool in studying the proliferation of neuroblastoma. BML-190 diminishes LPS-induced NO and IL-6 production in a concentration-dependent manner. BML-190 also inhibits LPS-induced PGE2 production and COX-2 induction. in vivo: |
StorageTemperature |
-20°C, 3 years; 4°C, 2 years (Powder) |
Shipping |
Room Temperature |
Manufacturers Applications |
Cancer-programmed cell death |
MolecularWeight |
426.89 |
Clinical Information |
No Development Reported |
Manufacturers Research Area |
Cancer |
Solubility |
DMSO : 50 mg/mL (ultrasonic) |
Target |
Cannabinoid Receptor |
Manufacturers Target |
Cannabinoid Receptor |
Manufacturers Pathway |
GPCR/G Protein; Neuronal Signaling |
Manufacturers Product type |
Reference compound |
Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.
All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.